Detection and Characterization of Infections and Infection Susceptibility
NCT00404560
Recruiting
This screening study will examine the causes of immune disorders affecting white blood cells, which defend against infections and will try to develop better means of diagnosis and treatment of these immune disorders. This is a 2 visit screening study and patients determined to be of interest for additional study or treatment will be asked to provide consent for enrollment into an appropriate NIH follow up study. This study does not cover the cost of the first visit to NIH for travel or lodgings... Read More
Gender:
ALL
Ages:
Between 1 month and 100 years
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immune Deficiencies
Register for Updates
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
Recruiting
Background: Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes cause this cancer to form. This may help them find new ways to treat it. Objective: - To perform DNA sequencing to help researchers learn the differences between normal tissue and tumor tissue. Also, to learn how molecular changes - including gene changes - might help predict the course of disease and how people respond to therapy. Elig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Bladder Cancer, Urinary Tract Cancer, Urothelial Cancer, Healthy Volunteers
Register for Updates
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
NCT03109288
Recruiting
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to. Objective: To see if signs of inflammation in CSF help predict a person s response to different drugs. Eligibility: People ages 18 and older who: * Are in protocol 09-I-003... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT04071236
Recruiting
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as radium-223 dichloride, may carry radiation directly to tumor cells and not harm norm... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +29 locations
Conditions: Stage IV Prostate Cancer AJCC v8, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Register for Updates
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT04339764
Recruiting
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease. Objective: To test the safety of putting cells inside the eye as a possible future treatment for dry age-related macular degeneration. Eligibility: People ages 55 and older who have geographic atrophy with loss of visi... Read More
Gender:
ALL
Ages:
Between 55 years and 95 years
Trial Updated:
04/25/2025
Locations: Johns Hopkins University, Baltimore, Maryland +1 locations
Conditions: Dry Age-Related Macular Degeneration, Geographic Atrophy
Register for Updates
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
NCT04703244
Recruiting
Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Breast Cancer, Residual
Register for Updates
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Arizona Arthritis and Rheumatology Research PLLC, Avondale, Arizona +239 locations
Conditions: Arthritis, Psoriatic
Register for Updates
Medrol Dosepak for Outpatient Total Knee Arthroplasty
NCT05097976
Recruiting
The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on acute postoperative pain, function, opioid consumption, nausea, and complications following outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will be associated with improved pain and decreased opioid use, nausea, and complications at POD1-7, as compared to similar patients who receive pla... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Rush Oak Brook Outpatient Center, Oak Brook, Illinois
Conditions: Total Knee Arthroplasty
Register for Updates
Food Prescriptions to Promote Affordable Diets
NCT05309395
Recruiting
This is an Randomized controlled trial (RCT) to assess the impact of meal planning and affordable grocery delivery on weight loss, dietary quality and health on members of multigenerational Latino households.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/25/2025
Locations: Kaiser Permanente, Pasadena, California
Conditions: Diet, Healthy, Overweight and Obesity
Register for Updates
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Recruiting
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: The University of Arizona Cancer Center, Tucson, Arizona +215 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette)
NCT05626114
Recruiting
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/25/2025
Locations: Retina-Vitreous Associates Medical Group, Beverly Hills, California +6 locations
Conditions: Geographic Atrophy
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +997 locations
Conditions: Acute Coronary Syndrome
Register for Updates